Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments

Rhea-AI Summary

Clarivate (NYSE:CLVT) has announced the integration of Pathway Maps into its OFF-X translational safety intelligence solution. This enhancement aims to streamline safety evaluations in drug development, addressing the critical issue where over 30% of drug development failures are attributed to safety concerns.

The new Pathway Maps feature provides visual tools that combine disease-specific signaling pathways and molecular processes with curated safety data, enabling researchers to quickly identify potential safety liabilities. This integration helps research teams make faster, more informed decisions during the drug development process, from early discovery to post-marketing surveillance.

The enhanced OFF-X platform, when combined with Cortellis Drug Discovery Intelligence, offers researchers a comprehensive approach to evaluate both efficacy and safety in drug development, helping reduce costly late-stage failures and accelerate time to market.

Positive

• Integration of visual pathway maps with safety data streamlines target safety assessments
• Addresses 30% drug development failure rate due to safety issues
• Potential reduction in costly late-stage drug development failures
• Enhanced capability for early safety liability identification

Negative

• None.

News Market Reaction – CLVT

+1.35%

1 alert

+1.35% News Effect

On the day this news was published, CLVT gained 1.35%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights

LONDON, May 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution. With over 30% of drug development failures attributed to safety issues¹, preclinical and translational research teams face increasing pressure to identify potential liabilities earlier in the target selection process. Pathway Maps provide powerful visual tools that offer deeper insights into the biological mechanisms underlying diseases and target interactions, streamlining target safety assessments and enabling faster, data-driven decisions.

Traditional safety data collection is often fragmented and time-consuming, creating delays in critical go/no-go decisions. With the addition of Pathway Maps to OFF-X, researchers can now explore disease-specific visualizations of key signaling pathways and molecular processes—uniquely overlaid with curated, multi-source safety data. This integration enables users to quickly pinpoint potential safety liabilities across upstream or downstream targets, adding biological context to risk assessment. By bringing together visual disease biology and comprehensive safety intelligence in one platform, OFF-X addresses a critical industry gap—empowering teams to make faster, more confident decisions across the drug development lifecycle.

Anne Lecocq, SVP and GM, R&D, Life Sciences & Healthcare, Clarivate, said: "The ability to assess the safety of drug targets early in development is a critical factor in reducing costly late-stage failures and accelerating time to market. At Clarivate, we're committed to empowering our customers with tools that not only streamline their workflows but also provide deeper, more actionable insights that improve patient lives and create a healthier tomorrow. The introduction of Pathway Maps into OFF-X is a game-changer—it integrates complex biological data with curated safety intelligence, helping researchers make confident, data-driven decisions faster and with greater accuracy."

With this release, OFF-X reaffirms its unique position as a platform that integrates proprietary physiological and disease pathway visualizations with curated safety data from diverse sources. This integration streamlines data access and enhances risk evaluation, providing researchers with the confidence to make more informed decisions and refine mitigation strategies.

Designed to support researchers throughout the drug development lifecycle—from early discovery to post-marketing surveillance— OFF-X offers a unified resource for translational safety intelligence. In the drug discovery and preclinical space, the combination OFF-X and Cortellis Drug Discovery Intelligence provides the most powerful approach for researchers to cover both efficacy and safety.

For more information on how OFF-X helps optimize target safety assessments, visit here.

About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare.  For more information, please visit clarivate.com

1	Source: Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet. 2011;26(1):3-14. doi: 10.2133/dmpk.dmpk-10-rv-062. Epub October 22, 2010. PMID: 20978361; PMCID: PMC4707670.

Media Contact:

Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-enhances-off-x-with-pathway-maps-to-accelerate-target-safety-assessments-302453110.html

SOURCE Clarivate Plc

FAQ

What is the new feature added to Clarivate's OFF-X platform in May 2024?

Clarivate added Pathway Maps to OFF-X, a feature that provides visual tools for understanding biological mechanisms and target interactions, integrated with curated safety data.

How does Pathway Maps in OFF-X help drug development researchers?

Pathway Maps helps researchers by providing visual disease-specific signaling pathways combined with safety data, enabling faster identification of potential safety liabilities and more informed decision-making in drug development.

What percentage of drug development failures are caused by safety issues according to Clarivate?

According to Clarivate, over 30% of drug development failures are attributed to safety issues.

How does OFF-X integrate with Cortellis Drug Discovery Intelligence?

The combination of OFF-X and Cortellis Drug Discovery Intelligence provides researchers with a comprehensive approach to evaluate both efficacy and safety in drug development.